CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Seoul, Korea, Republic of and 145 other locations
of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and ...
Phase 1
Seoul, Korea, Republic of and 21 other locations
doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapi...
Phase 1
Seoul, Korea, Republic of and 19 other locations
phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...
Phase 1
Seoul, Korea, Republic of and 40 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of and 239 other locations
with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).All eligible subjects must be previously treate...
Phase 1, Phase 2
Seoul, Korea, Republic of and 53 other locations
(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...
Phase 3
Seoul, Korea, Republic of and 143 other locations
(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...
Phase 3
Seoul, Korea, Republic of and 129 other locations
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...
Phase 3
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 82 other locations
antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...
Phase 1
Seoul, Korea, Republic of and 25 other locations
Clinical trials
Research sites
Resources
Legal